Home›Trial›NCT04644068
🔬NCT04644068Phase 1Phase 2ACTIVE NOT RECRUITING

Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies

Study Summary

This research is designed to determine if experimental treatment with PARP inhibitor, AZD5305, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced solid tumors.

Conditions
Ovarian CancerBreast CancerPancreatic CancerProstate CancerAdditional Indications Below for Module 4 and 5Non-small Cell Lung CancerColorectal CancerBladder CancerGastric CancerBiliary CancerCervical CancerEndometrial CancerSmall Cell Lung Cancer Only in Module 5
Interventions / Drugs
AZD5305PaclitaxelCarboplatinT- DxdDato-DXdCamizestrant
View on ClinicalTrials.gov ↗
Sponsor
AZN
AstraZeneca
Oncology/Respiratory
F15/100
Study Details
Enrollment702 participants
Primary Completion—
Lead SponsorAstraZeneca
Data Retrieved2026-04-11 02:55:19.910050+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.